Regeneron developing antibodies to target omicron as current cocktail loses potency against variant

Regeneron developing antibodies to target omicron as current cocktail loses potency against variant

CEO Leonard Schleifer told CNBC Regeneron plans to conduct trials on the new antibodies in the first quarter of 2022.

Post a Comment